Lifotronic(SH:688389) Sou Hu Cai Jing·2025-05-06 13:14Core Viewpoint - Pumen Technology's stock closed at 13.05 yuan, with a rolling PE ratio of 19.16 times, significantly lower than the industry average of 48.90 times, indicating potential undervaluation in the medical device sector [1][2]. Company Overview - Pumen Technology specializes in the research, manufacturing, global sales, and service of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2]. - The company's main products include medical products, home products, testing equipment, and testing reagents [2]. Recent Achievements - In January 2024, Pumen Technology was awarded the title of "Demonstration Enterprise for Smart Health and Elderly Care Application Pilot" by three ministries [2]. - The project "Micro-tube Inner Surface Wear-resistant Superhydrophobic Coating and Its Application in Medical Devices" won the first prize of the "2023 China Corrosion and Protection Society Science and Technology Award" [2]. - Pumen Technology's subsidiary, Guangdong Pumen Biomedical Technology Co., Ltd., was recognized as a "Specialized, Refined, Characteristic, and Innovative Small and Medium-sized Enterprise" by the Guangdong Provincial Department of Industry and Information Technology [2]. - A collaborative project with Chongqing University on "Key Technology Development and Industrialization of Fully Automatic Specific Protein Analyzers" received the second prize of the "2023 China Industry-University-Research Cooperation Innovation Achievement Award" [2]. Financial Performance - For Q1 2025, Pumen Technology reported revenue of 215 million yuan, a year-on-year decrease of 29.69%, and a net profit of 53.68 million yuan, down 49.93% [2]. - The company's gross profit margin stood at 64.97% [2]. Market Position - Pumen Technology ranks 45th in the medical device industry based on PE ratio, with an average industry PE of 48.90 times and a median of 36.41 times [1][3].